Nuveen LLC Acquires Shares of 89,141 Capricor Therapeutics, Inc. $CAPR

Nuveen LLC acquired a new stake in shares of Capricor Therapeutics, Inc. (NASDAQ:CAPR) during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 89,141 shares of the biotechnology company’s stock, valued at approximately $846,000. Nuveen LLC owned approximately 0.20% of Capricor Therapeutics as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in CAPR. Nuveen Asset Management LLC raised its position in shares of Capricor Therapeutics by 392.7% in the fourth quarter. Nuveen Asset Management LLC now owns 169,111 shares of the biotechnology company’s stock valued at $2,334,000 after buying an additional 134,791 shares during the last quarter. The Manufacturers Life Insurance Company raised its position in shares of Capricor Therapeutics by 22.4% in the fourth quarter. The Manufacturers Life Insurance Company now owns 12,919 shares of the biotechnology company’s stock valued at $178,000 after buying an additional 2,361 shares during the last quarter. Two Sigma Investments LP raised its position in shares of Capricor Therapeutics by 223.6% in the fourth quarter. Two Sigma Investments LP now owns 119,047 shares of the biotechnology company’s stock valued at $1,643,000 after buying an additional 82,254 shares during the last quarter. Voya Investment Management LLC acquired a new stake in shares of Capricor Therapeutics in the fourth quarter valued at about $150,000. Finally, Bank of America Corp DE raised its position in shares of Capricor Therapeutics by 938.9% in the fourth quarter. Bank of America Corp DE now owns 170,543 shares of the biotechnology company’s stock valued at $2,353,000 after buying an additional 154,127 shares during the last quarter. 21.68% of the stock is owned by hedge funds and other institutional investors.

Capricor Therapeutics Price Performance

Shares of CAPR opened at $6.33 on Wednesday. Capricor Therapeutics, Inc. has a 1-year low of $3.98 and a 1-year high of $23.40. The stock has a market cap of $289.41 million, a PE ratio of -3.86 and a beta of 0.73. The firm has a 50-day simple moving average of $8.00 and a two-hundred day simple moving average of $10.30.

Capricor Therapeutics (NASDAQ:CAPR) last announced its quarterly earnings results on Monday, August 11th. The biotechnology company reported ($0.57) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.09). Capricor Therapeutics had a negative net margin of 181.71% and a negative return on equity of 62.71%. As a group, sell-side analysts expect that Capricor Therapeutics, Inc. will post -1.21 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

CAPR has been the subject of a number of recent research reports. B. Riley initiated coverage on shares of Capricor Therapeutics in a research report on Thursday, June 26th. They issued a “buy” rating and a $21.00 target price for the company. Alliance Global Partners reiterated a “buy” rating on shares of Capricor Therapeutics in a research report on Monday, July 14th. HC Wainwright reduced their target price on shares of Capricor Therapeutics from $77.00 to $24.00 and set a “buy” rating for the company in a research report on Friday, July 11th. Oppenheimer cut their price objective on shares of Capricor Therapeutics from $43.00 to $22.00 and set an “outperform” rating for the company in a research report on Monday, June 23rd. Finally, Wall Street Zen cut shares of Capricor Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, May 22nd. One research analyst has rated the stock with a Strong Buy rating and eight have issued a Buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $22.56.

About Capricor Therapeutics

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.